BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00

Reuters

Jul 31, 2025

July 31 (Reuters) - Biogen Inc BIIB.O:

BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLION
BIOGEN -Q2 NON-GAAP DILUTED EPS $5.47
BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00
BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT ($0.26) IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTER
BIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCY
BIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025
BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025
BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&A EXPENSE TO TOTAL APPROXIMATELY $4.0 BILLION IN 2025
BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFS

Further company coverage: BIIB.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555886907"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555886907\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555886907?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555886907","market":"us","top_or_hot":-1,"title":"BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00</title></head><body><p><span>July 31 (Reuters)</span><span> - </span>Biogen Inc <span>BIIB.O</span>:</p><ul><li><p>BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLION</p></li><li><p>BIOGEN -<a href=\"https://laohu8.com/S/QTWO\">Q2</a> NON-GAAP DILUTED EPS $5.47</p></li><li><p>BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00</p></li><li><p>BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT ($0.26) IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTER</p></li><li><p>BIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCY</p></li><li><p>BIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025</p></li><li><p>BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025</p></li><li><p>BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&amp;A EXPENSE TO TOTAL APPROXIMATELY $4.0  BILLION IN 2025</p></li><li><p>BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFS</p></li></ul><p>Further company coverage: <span>BIIB.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 18:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00</title></head><body><p><span>July 31 (Reuters)</span><span> - </span>Biogen Inc <span>BIIB.O</span>:</p><ul><li><p>BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLION</p></li><li><p>BIOGEN -<a href=\"https://laohu8.com/S/QTWO\">Q2</a> NON-GAAP DILUTED EPS $5.47</p></li><li><p>BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00</p></li><li><p>BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT ($0.26) IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTER</p></li><li><p>BIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCY</p></li><li><p>BIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025</p></li><li><p>BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025</p></li><li><p>BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&amp;A EXPENSE TO TOTAL APPROXIMATELY $4.0  BILLION IN 2025</p></li><li><p>BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFS</p></li></ul><p>Further company coverage: <span>BIIB.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS1F5:1","article_id":"2555886907","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555886907","pubTimestamp":1753957024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00July 31  - Biogen Inc BIIB.O:BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLIONBIOGEN -Q2 NON-GAAP DILUTED EPS $5.47BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT  IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTERBIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCYBIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&A EXPENSE TO TOTAL APPROXIMATELY $4.0  BILLION IN 2025BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFSFurther company coverage: BIIB.O","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"简介-Biogen展望2025年非GAAP稀释每股收益15.50美元至16.00美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9},"content_text":"BRIEF-Biogen Outlook 2025 Non-GAAP Diluted EPS $15.50 To $16.00July 31 (Reuters) - Biogen Inc BIIB.O:BIOGEN -SECOND QUARTER 2025 TOTAL REVENUE $2.6 BILLIONBIOGEN -Q2 NON-GAAP DILUTED EPS $5.47BIOGEN - OUTLOOK FULL YEAR 2025 NON-GAAP DILUTED EPS $15.50 TO $16.00BIOGEN -NON-GAAP DILUTED EPS INCLUDES ABOUT ($0.26) IMPACT FROM $47 MILLION OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT EXPENSE IN QUARTERBIOGEN -INCREASED EXPECTED FULL YEAR 2025 TOTAL REVENUE TO BE APPROXIMATELY FLAT, AT CONSTANT CURRENCYBIOGEN -EXPECTS INCREASED COMPETITIVE PRESSURES ON EX- U.S. MS BUSINESS IN SECOND HALF OF 2025BIOGEN -EXPECTS MINIMAL CONTRACT MANUFACTURING REVENUE IN FOURTH QUARTER OF 2025BIOGEN -EXPECTS COMBINED NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE AND NON-GAAP SG&A EXPENSE TO TOTAL APPROXIMATELY $4.0  BILLION IN 2025BIOGEN -2025 FINANCIAL OUTLOOK IS NOT CURRENTLY EXPECTED TO BE MATERIALLY IMPACTED BY POTENTIAL TARIFFSFurther company coverage: BIIB.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}